Key points are not available for this paper at this time.
在新诊断晚期卵巢癌患者中，对铂基化疗有反应的患者，接受尼拉帕尼治疗者的无进展生存期显著长于接受安慰剂者，无论是否存在同源重组缺陷。（资助方：葛兰素史克；临床试验编号 PRIMA/ENGOT-OV26/GOG-3012 ClinicalTrials.gov 编号 NCT02655016。）
Building similarity graph...
Analyzing shared references across papers
Loading...
Antonio González-Martı́n
Bhavana Pothuri
Ignace Vergote
New England Journal of Medicine
Cornell University
University of Pennsylvania
McGill University
Building similarity graph...
Analyzing shared references across papers
Loading...
González-Martı́n 等人（星期六）研究了该问题。
www.synapsesocial.com/papers/69d77af93fae90fd6048f479 — DOI: https://doi.org/10.1056/nejmoa1910962